Modalis Therapeutics Corporation Share Price
Equities
4883
JP3922600006
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
77 JPY | 0.00% | -1.28% | -37.90% |
15/04 | Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs | MT |
23/02 | Modalis Therapeutics to Reduce Stated Capital and Capital Reserves | MT |
Sales 2022 | 40M 253K 21.06M | Sales 2023 | - | Capitalization | 3.92B 24.76M 2.06B |
---|---|---|---|---|---|
Net income 2022 | -2.7B -17.09M -1.42B | Net income 2023 | -2.39B -15.12M -1.26B | EV / Sales 2022 | 171 x |
Net cash position 2022 | 2.93B 18.55M 1.54B | Net cash position 2023 | 1.47B 9.3M 774M | EV / Sales 2023 | - |
P/E ratio 2022 |
-3.61
x | P/E ratio 2023 |
-1.61
x | Employees | 37 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 83.39% |
1 week | -1.28% | ||
Current month | -19.79% | ||
1 month | -17.20% | ||
3 months | -32.46% | ||
6 months | -42.96% | ||
Current year | -37.90% |
Managers | Title | Age | Since |
---|---|---|---|
Haru Morita
FOU | Founder | 54 | 01/16/01 |
Naoki Kobayashi
DFI | Director of Finance/CFO | 60 | - |
Tetsuya Yamagata
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph McCracken
BRD | Director/Board Member | 70 | 01/18/01 |
Toshio Furuta
BRD | Director/Board Member | 62 | 01/18/01 |
Haru Morita
FOU | Founder | 54 | 01/16/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 77 | 0.00% | 147,800 |
25/24/25 | 77 | 0.00% | 89,000 |
24/24/24 | 77 | 0.00% | 164,600 |
23/24/23 | 77 | -2.53% | 499,500 |
22/24/22 | 79 | +1.28% | 191,100 |
Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
-37.90% | 16.73M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- 4883 Stock